# Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

> **NCT00309985** · PHASE3 · COMPLETED · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 790 (actual)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer

## Interventions

- **DRUG:** androgen-deprivation therapy
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00309985
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-26
- **Primary completion:** 2013-12-23
- **Final completion:** 2025-01-31
- **Target enrollment:** 790 (ACTUAL)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309985, "Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00309985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*